Aevi Genomic Medicine, Inc. (GNMX) financial statements (2021 and earlier)

Company profile

Business Address 435 DEVON PARK DRIVE,
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 123440533322
Cash and cash equivalents 123440533322
Other undisclosed current assets 010100
Total current assets: 123540543423
Noncurrent Assets
Property, plant and equipment 000000
Restricted cash and investments 000000
Other noncurrent assets  0    
Other undisclosed noncurrent assets     00
Total noncurrent assets: 000010
TOTAL ASSETS: 123541543423
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 335332
Accounts payable 210 1 
Employee-related liabilities 012222
Other undisclosed accounts payable and accrued liabilities 1131(0)0
Other undisclosed current liabilities 210111
Total current liabilities: 446443
Noncurrent Liabilities
Liabilities, other than long-term debt      1
Derivative instruments and hedges, liabilities      1
Other undisclosed noncurrent liabilities     10
Total noncurrent liabilities:     12
Total liabilities: 446455
Stockholders' equity
Stockholders' equity attributable to parent, including: 83135503018
Common stock 000000
Additional paid in capital 254246215188130100
Accumulated deficit (246)(215)(180)(138)(100) 
Other undisclosed stockholders' equity attributable to parent      (82)
Total stockholders' equity: 83135503018
TOTAL LIABILITIES AND EQUITY: 123541543423

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses (9)(35)(42)(28)(19)(17)
Other undisclosed operating loss (22)  (8)(0)(0)
Operating loss: (31)(35)(42)(37)(19)(18)
Nonoperating income (expense) 0(0)(0)(1)10
Investment income, nonoperating     00
Other nonoperating income (expense) 0(0)(0)(1)1 
Loss from continuing operations before equity method investments, income taxes: (31)(35)(42)(38)(18)(18)
Other undisclosed income (loss) from continuing operations before income taxes     (0)1
Loss from continuing operations before income taxes: (31)(35)(42)(38)(18)(17)
Income tax expense   (0)(0)(0)(0)
Net loss attributable to parent: (31)(35)(42)(38)(18)(17)
Other undisclosed net income available to common stockholders, basic   84763717
Net income (loss) available to common stockholders, basic: (31)(35)4238180
Dilutive securities, effect on basic earnings per share    11 
Net income (loss) available to common stockholders, diluted: (31)(35)4239190

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (31)(35)(42)(38)(18)(17)
Comprehensive loss, net of tax, attributable to parent: (31)(35)(42)(38)(18)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: